1637443-98-1
Chemical Structure
hVEGF-IN-1
- CAS No.: 1637443-98-1
- Formula:C34H43N7O2
- Molecular Weight:581.75
IUPAC Name: N-(2-(4-((4-(2-(diethylamino)ethoxy)phenyl)amino)quinazolin-2-yl)phenyl)-3-(4-methylpiperazin-1-yl)propanamide
InChIKey: VIBJAHJNWHZSJP-UHFFFAOYSA-N
SMILES: CCN(CC)CCOC(C=C1)=CC=C1NC2=NC(C3=C(NC(CCN4CCN(C)CC4)=O)C=CC=C3)=NC5=CC=CC=C52
Biological Activity: hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
hVEGF-IN-1 | 99.25% | hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
hVEGF-IN-1 (Standard) | ≥98% | hVEGF-IN-1 (Standard) is the analytical standard of hVEGF-IN-1 (HY-101931). This product is intended for research and analytical applications. hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
